Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.

Background: High aldosterone level may contribute to pathogenesis of hypertension, vessels damage and cardiovascular system deterioration in chronic kidney disease patients. Besides its classical action via mineralocorticoid receptor, aldosterone is also involved in cell growth, inflammation, oxidative stress, endothelial dysfunction and exerts fibroproliferative effects. The aim of the study was to assess whether aldosterone antagonist treatment may influence serum level of inflammatory, fibrosis, thrombosis and mineral-bone metabolism markers in peritoneal dialysis (PD) patients and blood pressure, aortic stiffness, echocardiographic indices after 12 months of treatment.

[HIV-associated nephropathy. Case report].

The clinical case described below forces us to ask two basic questions: whether the patient is suffering from two separate, co-existing illnesses, i.e. primary nephritic syndrome or the nephritic syndrome in connection with Schoenlein-Henoch disease, with accompanies the HIV infection, or nephropathy, development of which has been triggered by HIV infection.